OPCH on Nasdaq
Option Care Health, Inc.
American home health care services company based in Bannockburn2
In its 2026 annual report the company says: “Option Care Health, Inc. is the largest independent provider of home and alternate site infusion services through its national network of 196 locations in 43 states.”5 Its shares trade on Nasdaq under the symbol OPCH.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with AdaptHealth Corp., Chemed Corporation or BrightSpring Health Services, Inc., or pick any stock.
- TickerOPCH on Nasdaq2
- IndustryServices-Home Health Care Services2
- HeadquartersBannockburn, United States2
- Incorporated inDE3
- Business address3000 Lakeside Dr, Suite 300N, Bannockburn, Il 600153
- Filer categoryLarge accelerated filer3
- Legal formCorporation2
- LEI549300DI3Q5ACSYJRI172
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 26057392
See how the biggest companies compare on our leaderboards
Option Care Health, Inc. (“Option Care Health”, “we”, “us”, “our”, or the “Company”) is the largest independent provider of home and alternate site infusion services through its national network of 196 locations in 43 states. Option Care Health draws on over 40 years of clinical care experience to offer patient-centered, cost-effective infusion therapy. Option Care Health’s infusion services include the clinical management of infusion therapy, nursing support and care coordination. Option Care Health’s multidisciplinary team of more than 5,000 clinicians, including pharmacists, pharmacy technicians, nurses and dietitians, are able to provide infusion service coverage for nearly all patients across the United States (“U.S.”) needing treatment for complex and chronic medical conditions.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
19.3%Gross margin6
6.0%Operating margin6
3.7%Net margin6
13.0%Revenue growth, 20256
15.7%Return on equity6
0.87×Debt to equity6
$217.1MFree cash flow6
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue81¢$4.6B
- Selling, general and admin12¢$682.5M
- Other costs2¢$122.5M
- Income tax1¢$75.3M
- Profit4¢$207.6M
Out of $5.6B in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Capital spending12¢$41.3M
- Share buybacks88¢$310.0M
Out of $258.4M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| NET REVENUE | $5.6B | $5.0B | $4.3B |
| COST OF REVENUE | $4.6B | $4.0B | $3.3B |
| GROSS PROFIT | $1.1B | $1.0B | $981.2M |
| Selling, general and administrative expenses | $682.5M | $630.3M | $607.4M |
| Depreciation and amortization expense | $67.5M | $60.9M | $59.2M |
| Total operating expenses | $750.0M | $691.2M | $666.6M |
| OPERATING INCOME | $337.9M | $321.8M | $314.6M |
| Interest expense, net | -$54.6M | -$49.0M | -$51.2M |
| Equity in earnings of joint ventures | $7.4M | $6.0M | $5.5M |
| Other, net | -$7.9M | $4.8M | $89.9M |
| Total other (expense) income | -$55.0M | -$38.2M | $44.1M |
| INCOME BEFORE INCOME TAXES | $282.9M | $283.6M | $358.7M |
| INCOME TAX EXPENSE | $75.3M | $71.8M | $91.7M |
| NET INCOME | $207.6M | $211.8M | $267.1M |
| Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $2,272, $1,284, and $2,158, respectively | -$6.9M | -$3.9M | -$6.2M |
| OTHER COMPREHENSIVE (LOSS) INCOME | -$6.9M | -$3.9M | -$6.2M |
| NET COMPREHENSIVE INCOME | $200.6M | $207.9M | $260.9M |
| Earnings per share, basic (in dollars per share) | $1.28 | $1.23 | $1.49 |
| Earnings per share, diluted (in dollars per share) | $1.27 | $1.23 | $1.48 |
| Weighted average common shares outstanding, basic (in shares) | 162.1M shares | 171.6M shares | 179.0M shares |
| Weighted average common shares outstanding, diluted (in shares) | 163.4M shares | 172.8M shares | 180.4M shares |
| Change in unrealized (loss) gain on cash flow hedges, income tax benefit (expense) | $2.3M | $1.3M | $2.2M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $232.6M | $412.6M | ||
| Accounts receivable, net | $473.6M | $409.7M | ||
| Inventories | $471.1M | $388.1M | ||
| Prepaid expenses and other current assets | $87.6M | $112.2M | ||
| Total current assets | $1.3B | $1.3B | ||
| Property and equipment, net | $139.2M | $127.4M | ||
| Operating lease right-of-use asset | $91.2M | $86.5M | ||
| Intangible assets, net | $21.9M | $17.0M | ||
| Referral sources, net | $287.3M | $284.0M | ||
| Goodwill | $1.6B | $1.5B | $1.5B | $1.5B |
| Other noncurrent assets | $44.4M | $44.0M | ||
| Total noncurrent assets | $2.2B | $2.1B | ||
| TOTAL ASSETS | $3.5B | $3.4B | ||
| Accounts payable | $639.8M | $610.8M | ||
| Accrued compensation and employee benefits | $70.4M | $63.0M | ||
| Accrued expenses and other current liabilities | $88.3M | $77.8M | ||
| Current portion of operating lease liability | $24.0M | $22.0M | ||
| Current portion of long-term debt | $6.8M | $6.5M | ||
| Total current liabilities | $829.3M | $780.1M | ||
| Long-term debt, net of discount, deferred financing costs and current portion | $1.2B | $1.1B | ||
| Operating lease liability, net of current portion | $88.5M | $84.8M | ||
| Deferred income taxes | $56.0M | $47.6M | ||
| Other noncurrent liabilities | $1.4M | $366.0K | ||
| Total noncurrent liabilities | $1.3B | $1.2B | ||
| Total liabilities | $2.1B | $2.0B | ||
| Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock; $0.0001 par value: 250,000,000 shares authorized, 184,522,423 shares issued and 156,857,801 shares outstanding as of December 31, 2025; 183,846,725 shares issued and 166,261,112 shares outstanding as of December 31, 2024 | $18.0K | $18.0K | ||
| Treasury stock; 27,664,622 and 17,585,613 shares outstanding, at cost, as of December 31, 2025 and 2024, respectively | -$818.2M | -$507.6M | ||
| Paid-in capital | $1.3B | $1.2B | ||
| Retained earnings | $876.9M | $669.3M | ||
| Accumulated other comprehensive income (loss) | $4.1M | $11.0M | ||
| Total stockholders equity | $1.3B | $1.4B | $1.4B | $1.4B |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $3.5B | $3.4B | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 12.5M shares | 12.5M shares | ||
| Preferred stock, shares, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | ||
| Common stock, shares, issued (in shares) | 184.5M shares | 183.8M shares | ||
| Common stock, shares, outstanding (in shares) | 156.9M shares | 166.3M shares | ||
| Treasury stock, shares (in shares) | 27.7M shares | 17.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $232.6M | $412.6M | ||
| Accounts receivable, net | $473.6M | $409.7M | ||
| Inventories | $471.1M | $388.1M | ||
| Prepaid expenses and other current assets | $87.6M | $112.2M | ||
| Total current assets | $1.3B | $1.3B | ||
| Property and equipment, net | $139.2M | $127.4M | ||
| Operating lease right-of-use asset | $91.2M | $86.5M | ||
| Intangible assets, net | $21.9M | $17.0M | ||
| Referral sources, net | $287.3M | $284.0M | ||
| Goodwill | $1.6B | $1.5B | $1.5B | $1.5B |
| Other noncurrent assets | $44.4M | $44.0M | ||
| Total noncurrent assets | $2.2B | $2.1B | ||
| TOTAL ASSETS | $3.5B | $3.4B | ||
| Accounts payable | $639.8M | $610.8M | ||
| Accrued compensation and employee benefits | $70.4M | $63.0M | ||
| Accrued expenses and other current liabilities | $88.3M | $77.8M | ||
| Current portion of operating lease liability | $24.0M | $22.0M | ||
| Current portion of long-term debt | $6.8M | $6.5M | ||
| Total current liabilities | $829.3M | $780.1M | ||
| Long-term debt, net of discount, deferred financing costs and current portion | $1.2B | $1.1B | ||
| Operating lease liability, net of current portion | $88.5M | $84.8M | ||
| Deferred income taxes | $56.0M | $47.6M | ||
| Other noncurrent liabilities | $1.4M | $366.0K | ||
| Total noncurrent liabilities | $1.3B | $1.2B | ||
| Total liabilities | $2.1B | $2.0B | ||
| Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock; $0.0001 par value: 250,000,000 shares authorized, 184,522,423 shares issued and 156,857,801 shares outstanding as of December 31, 2025; 183,846,725 shares issued and 166,261,112 shares outstanding as of December 31, 2024 | $18.0K | $18.0K | ||
| Treasury stock; 27,664,622 and 17,585,613 shares outstanding, at cost, as of December 31, 2025 and 2024, respectively | -$818.2M | -$507.6M | ||
| Paid-in capital | $1.3B | $1.2B | ||
| Retained earnings | $876.9M | $669.3M | ||
| Accumulated other comprehensive income (loss) | $4.1M | $11.0M | ||
| Total stockholders equity | $1.3B | $1.4B | $1.4B | $1.4B |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $3.5B | $3.4B | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 12.5M shares | 12.5M shares | ||
| Preferred stock, shares, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | ||
| Common stock, shares, issued (in shares) | 184.5M shares | 183.8M shares | ||
| Common stock, shares, outstanding (in shares) | 156.9M shares | 166.3M shares | ||
| Treasury stock, shares (in shares) | 27.7M shares | 17.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $207.6M | $211.8M | $267.1M |
| Depreciation and amortization expense | $70.7M | $63.5M | $62.2M |
| Non-cash operating lease costs | $25.0M | $22.6M | $18.5M |
| Deferred income taxes, net | $8.4M | $12.7M | $12.8M |
| Loss on extinguishment of debt | $4.7M | $377.0K | $0 |
| Amortization of deferred financing costs | $4.1M | $4.6M | $4.4M |
| Equity in earnings of joint ventures | -$7.4M | -$6.0M | -$5.5M |
| Stock-based incentive compensation expense | $40.0M | $36.1M | $30.5M |
| Distribution from equity method investments | $4.0M | $2.4M | $4.0M |
| Other adjustments | $1.0M | -$4.5M | -$1.2M |
| Accounts receivable, net | -$54.6M | -$32.1M | $224.0K |
| Inventories | -$81.5M | -$114.1M | -$51.0M |
| Prepaid expenses and other current assets | $17.8M | -$15.6M | -$6.3M |
| Accounts payable | $19.5M | $183.4M | $47.7M |
| Accrued compensation and employee benefits | $6.3M | -$29.5M | $15.5M |
| Accrued expenses and other current liabilities | $9.9M | $6.1M | -$1.7M |
| Operating lease liabilities | -$24.0M | -$21.9M | -$17.5M |
| Other noncurrent assets and liabilities | $6.9M | $3.4M | -$8.4M |
| Net cash provided by operating activities | $258.4M | $323.4M | $371.3M |
| Acquisition of property and equipment | -$41.3M | -$35.6M | -$41.9M |
| Proceeds from sale of assets | $0 | $0 | $3.7M |
| Business acquisitions, net of cash acquired | -$117.2M | $0 | -$12.5M |
| Other investing activities | -$2.5M | -$864.0K | -$5.9M |
| Net cash used in investing activities | -$161.1M | -$36.5M | -$56.5M |
| Stock-based compensation tax withholdings | -$10.6M | -$12.4M | -$3.1M |
| Purchase of company stock and related excise taxes | -$310.0M | -$252.7M | -$250.3M |
| Proceeds from issuance of debt | $229.5M | $50.0M | $0 |
| Repayments of debt principal | -$5.0M | -$6.4M | -$6.0M |
| Retirement of debt obligations | -$180.2M | $0 | $0 |
| Deferred financing costs | -$3.4M | -$77.0K | $0 |
| Other financing activities | $2.3M | $3.4M | -$5.8M |
| Net cash used in financing activities | -$277.3M | -$218.2M | -$265.1M |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | -$179.9M | $68.7M | $49.7M |
| Cash paid for interest | $64.7M | $71.6M | $69.8M |
| Income Taxes Paid, Net | $67.3M | $64.5M | $75.2M |
| Cash paid for operating leases | $30.7M | $28.5M | $27.4M |
No quarter-by-quarter statement was filed.
Corporate structure
Option Care Health, Inc. sits at the top of its group. 57 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Option Care Health, Inc.
- Durable Capital Partners LP Filed SCHEDULE 13G/A on Option Care Health, Inc., latest Aug 14, 2026 (2 filings since Jun 13, 2025)
- FMR LLC Filed SCHEDULE 13G/A on Option Care Health, Inc., latest May 6, 2026 (6 filings since Feb 9, 2022)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Option Care Health, Inc., latest Apr 30, 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on Option Care Health, Inc., latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Option Care Health, Inc., latest Mar 27, 2026 (5 filings since Feb 10, 2022)
- Wellington Management Company Filed SCHEDULE 13G/A on Option Care Health, Inc., latest Aug 12, 2025 (3 filings since Nov 8, 2024)
- BlackRock Filed SC 13G/A on Option Care Health, Inc., latest Jan 23, 2024 (4 filings since Feb 4, 2022)
- Walgreens Boots Alliance Filed SC 13D/A on Option Care Health, Inc., latest Jun 12, 2023 (4 filings since Dec 20, 2021)
- PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on Option Care Health, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- MADISON DEARBORN PARTNERS LLC Filed SC 13D/A on Option Care Health, Inc., latest Dec 20, 2021
- Option Care Health, Inc. Bannockburn, Illinois, United States
- OPTION CARE INFUSION SERVICES, INC. Subsidiary · 100% · Bannockburn, Illinois, United States
- BioScrip Infusion Services, Inc. Subsidiary · California, United States
- BioScrip PBM Services, LLC Subsidiary · Delaware, United States
- BioScrip Pharmacy Services, Inc. Subsidiary · Ohio, United States
- CHI Holding Corporation Subsidiary · Delaware, United States
- Chronimed, LLC Subsidiary · Minnesota, United States
- CHS Holdings, LLC Subsidiary · Delaware, United States
- Clinical Holdings, Inc. Subsidiary · Ohio, United States
- Clinical Specialties Network Services of Illinois, Inc. Subsidiary · Ohio, United States
- Clinical Specialties, Inc. Subsidiary · Ohio, United States
- Crescent Healthcare, Inc. Subsidiary · California, United States
- Critical Care Systems of New York, Inc. Subsidiary · New York, United States
- Critical Care Systems, LLC Subsidiary · Delaware, United States
- Critical Homecare Solutions, LLC Subsidiary · Delaware, United States
- CSI Managed Care, Inc. Subsidiary · Ohio, United States
- CSI Network Services of Indiana, Inc. Subsidiary · Ohio, United States
- CSI Network Services of Michigan, Inc. Subsidiary · Ohio, United States
- Deaconess Enterprises, LLC Subsidiary · Ohio, United States
- Deaconess HomeCare, LLC Subsidiary · Delaware, United States
- East Goshen Pharmacy, LLC Subsidiary · Pennsylvania, United States
- HC Group Holdings II, LLC Subsidiary · Delaware, United States
- HC Group Holdings III, Inc. Subsidiary · Delaware, United States
- Healthy Connections Homecare Services, Inc. Subsidiary · Texas, United States
- Home I.V. Specialists, Inc. Subsidiary · Arkansas, United States
- HomeChoice Partners, LLC Subsidiary · Delaware, United States
- and 31 more
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Option Care Health, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $269.1M6 Dec 31, 2025 | $247.9M6 Dec 31, 2024 | +8.5% |
| Accumulated depreciation | $129.8M6 Dec 31, 2025 | $120.5M6 Dec 31, 2024 | +7.7% |
| Property and equipment, net | $139.2M6 Dec 31, 2025 | $127.4M6 Dec 31, 2024 | +9.3% |
| Operating-lease assets (leased space) | $91.2M6 Dec 31, 2025 | $86.5M6 Dec 31, 2024 | +5.5% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $232.6M6 Dec 31, 2025 | $412.6M6 Dec 31, 2024 | −43.6% |
| Stakes in other companies (equity method) | $27.9M6 Dec 31, 2025 | $24.5M6 Dec 31, 2024 | +13.9% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $1.6B6 Dec 31, 2025 | $1.5B6 Dec 31, 2024 | +4.3% |
| Finite-lived intangibles, gross | $599.0M6 Dec 31, 2025 | $554.5M6 Dec 31, 2024 | +8.0% |
| Accumulated amortization | $289.8M6 Dec 31, 2025 | $253.5M6 Dec 31, 2024 | +14.3% |
| Finite-lived intangibles, net | $309.2M6 Dec 31, 2025 | $301.0M6 Dec 31, 2024 | +2.7% |
Inventory
Properties, in its own words
We currently lease all of our properties from third parties under various lease terms expiring over periods extending through 2039, in addition to a number of non-material month-to-month leases. Our corporate headquarters is located at 3000 Lakeside Drive, Suite 300N, Bannockburn, IL 60015. Our other properties mainly consist of infusion pharmacies equipped with clean room and compounding capabilities. Some infusion pharmacies are co-located with an ambulatory infusion center where patients receive infusion treatments. As of December 31, 2025, we have 87 pharmacies and 109 stand-alone ambulatory infusion suites that support our infusion services business in 43 states.
Item 2 of the 10-K filed Feb 24, 2026.5
Leadership
Who has led Option Care Health, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerJohn Charles Rademacher Aug 7, 2019 to now15
- Chief executive officerDaniel E. Greenleaf Sep 23, 2016 to May 20, 201916
- Chief executive officerRichard H. Friedman Nov 14, 2006 to Apr 28, 201117
- ChairRichard H. Friedman Nov 14, 2006 to Apr 28, 201117
- Chief financial officerMeenal Sethna Oct 3, 2025 to now18
- Chief financial officerMichael H. Shapiro Aug 7, 2019 to Oct 3, 202519
- Chief financial officerStephen Deitsch Apr 25, 2017 to May 20, 201920
- Chief financial officerJeffrey M. Kreger Apr 28, 2015 to Mar 17, 201721
- Chief financial officerHai Tran May 23, 2012 to Jun 2, 201422
- Chief financial officerMary Jane Graves Feb 7, 2011 to Feb 14, 201223
- Chief financial officerDavid W. Froesel Jr. Dec 3, 2010 to Dec 3, 201024
- Chief financial officerStanley Rosenbaum Jun 19, 2006 to Aug 5, 201025
- Chief operating officerLuke Whitworth Jan 25, 2023 to now26
- Chief operating officerHarriet Booker Nov 30, 2017 to Jun 8, 202227
- Chief operating officerJames C. Luthin Aug 11, 2015 to Jul 8, 201628
- Chief operating officerThomas F. Pettit Jul 21, 2014 to Oct 28, 201429
Board members and other officers (68)
- EVP Sp Sales & SolutionsPrateek Bhatia Jul 8, 2026 to now30
- Chief Medical OfficerFemi Adewunmi Apr 23, 2024 to now31
- Chief Accounting OfficerNicole Maggio Aug 9, 2024 to now32
- Chief Human Resources OfficerMichael Bavaro Jan 25, 2023 to now33
- Chief Growth OfficerChristopher L. Grashoff Dec 15, 2023 to now34
- Gen. Counsel & Corp. Secy.Collin Smyser Apr 22, 2022 to now35
- Chief Medical OfficerSeema Kumbhat Aug 19, 2021 to Feb 22, 202236
- CHIEF GROWTH OFFICERChristopher Frederick Hartman Aug 7, 2019 to Aug 7, 201937
- OfficerClifford E. Berman Aug 7, 2019 to Jul 13, 202138
- CHIEF ACCOUNTING OFFICERRobert R. Kampstra Aug 7, 2019 to Jul 13, 202139
- Chief Commercial OfficerRichard Denness Jul 17, 2018 to Mar 13, 202340
- Chief Human Resources OfficerLeslie McIntosh Aug 3, 2018 to Aug 3, 201841
- Chief Accounting OfficerGerald Anthony Lopez Dec 1, 2017 to Dec 1, 201742
- Senior Vice PresidentAlex Schott Sep 23, 2016 to May 7, 201843
- Chief Commercial OfficerGeorge Gregory Meadows Sep 23, 2016 to Sep 23, 201644
- Chief Compliance OfficerMelanie Sponholz Sep 23, 2016 to Sep 23, 201645
- Chief Compliance OfficerJody Kepler Dec 27, 2016 to Apr 11, 201946
- SVP Human ResourcesDonna Trujillo Jan 12, 2015 to Aug 11, 201547
- VP, Chief Accounting OfficerC. Britt Jeffcoat Jun 2, 2015 to Mar 17, 201748
- Chief Compliance OfficerBetty Y. Jang Nov 4, 2015 to Nov 4, 201549
- SVP, Chief Strategy OfficerKaren W. Cain May 30, 2014 to Sep 25, 201550
- SVP National Infusion SalesBrian Edward Stiver Mar 18, 2013 to Sep 25, 201551
- SVP Field OperationsDana Worden Soper Oct 1, 2013 to Nov 7, 201352
- Compliance OfficerBarbara Cormier Apr 3, 2012 to Apr 1, 201353
- Vice President, PBM ServicesDaniel Colucci Apr 3, 2012 to Jun 2, 201454
- Vice President, FinancePatricia Bogusz May 3, 2011 to Jun 2, 201455
- Senior Vice PresidentVito Ponzio Jr. May 3, 2011 to Jun 2, 201456
- SVP, Specialty ServicesMichael Saracco Jun 23, 2010 to Mar 12, 201257
- Executive Vice PresidentThomas Ordemann May 1, 2008 to Dec 1, 200958
- Vice President Mail OperationsRussel J. Corvese Apr 17, 2007 to Feb 13, 201359
- Executive Vice PresidentBarry A. Posner Nov 14, 2006 to Apr 28, 201160
- EVPBrian J. Reagan Nov 14, 2006 to Jan 21, 200961
- Board memberBarbara W. Bodem Jan 9, 2024 to now62
- Board memberNorman L. Wright Jan 9, 2024 to now63
- Board memberEric Brandt May 17, 2024 to now64
- Board memberAaron Friedman May 24, 2022 to May 24, 202265
- Board memberAnita M. Allemand May 24, 2022 to May 24, 202266
- Board memberElizabeth D. Bierbower May 24, 2022 to now67
- Board memberNatasha Deckmann May 24, 2022 to now68
- Board memberPaul J. Finnegan Jul 24, 2020 to Sep 21, 202169
- Board memberSamuel M. Mencoff Jul 24, 2020 to Sep 21, 202169
- Board memberAlan Troy Nielsen Aug 7, 2019 to May 13, 202070
- Board memberElizabeth Quadros Betten Aug 7, 2019 to now71
- Board memberHarry M. Jansen Kraemer Jr. Aug 7, 2019 to now72
- Board memberJohn Arlotta Aug 7, 2019 to May 17, 202473
- Board memberJohn Charles Rademacher Aug 7, 2019 to now15
- Board memberMark Edmund Vainisi Aug 7, 2019 to Aug 7, 201974
- Board memberNitin Sahney Aug 7, 2019 to Jun 7, 202375
- Board memberTimothy P. Sullivan Aug 7, 2019 to now76
- Board memberSteven Neumann Jan 30, 2017 to Jan 30, 201777
- Board memberMichael G. Bronfein Apr 21, 2016 to Jun 5, 201978
- Board memberAdam Gray Mar 11, 2015 to Jul 10, 201979
- Board memberChristopher S. Shackelton Mar 11, 2015 to Jul 10, 201979
- Board memberDavid W. Golding May 20, 2015 to now80
- Board memberMichael Goldstein May 20, 2015 to Jun 5, 201981
- Board memberR. Carter Pate May 20, 2015 to now82
- Board memberTricia Nguyen Jan 23, 2014 to May 4, 201783
- Board memberYon Jorden May 12, 2014 to Mar 13, 201584
- Board memberRichard H. Friedman Jun 3, 2008 to Apr 17, 201285
- Board memberSteven Karl Schelhammer May 22, 2007 to Apr 30, 200986
- Board memberCharlotte W. Collns May 24, 2006 to May 12, 201487
- Board memberStuart A. Samuels May 24, 2006 to May 12, 201488
- Board memberDavid R. Hubers May 25, 2006 to May 12, 201489
- Board memberLouis Difazio Dr. May 25, 2006 to Apr 28, 201190
- Board memberMichael Kooper May 25, 2006 to Jan 23, 200891
- Board memberMyron Z. Holubiak May 25, 2006 to Jun 2, 201692
- Board memberRichard L. Robbins May 25, 2006 to May 12, 201493
- General counselKathryn Stalmack Aug 14, 2018 to Apr 18, 201994
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- BioScrip Infusion Services, Inc. California4
- BioScrip Infusion Services, LLC Delaware4
- BioScrip PBM Services, LLC Delaware4
- BioScrip Pharmacy Services, Inc. Ohio4
- CHI Holding Corporation Delaware4
- CHS Holdings, LLC Delaware4
- CSI Managed Care, Inc. Ohio4
- CSI Network Services of Indiana, Inc. Ohio4
- CSI Network Services of Michigan, Inc. Ohio4
- Chronimed, LLC Minnesota4
- Clinical Holdings, Inc. Ohio4
- Clinical Specialties Network Services of Illinois, Inc. Ohio4
- Clinical Specialties, Inc. Ohio4
- Crescent Healthcare, Inc. California4
- Critical Care Systems of New York, Inc. New York4
- Critical Care Systems, LLC Delaware4
- Critical Homecare Solutions, LLC Delaware4
- Deaconess Enterprises, LLC Ohio4
- Deaconess HomeCare, LLC Delaware4
- East Goshen Pharmacy, LLC Pennsylvania4
- HC Group Holdings II, LLC Delaware4
- HC Group Holdings III, Inc. Delaware4
- Healthy Connections Homecare Services, Inc. Texas4
- Home I.V. Specialists, Inc. Arkansas4
All 58 listed subsidiaries
- HomeChoice Partners, LLC Delaware4
- InfuScience South Carolina, LLC Delaware4
- InfuScience, LLC Delaware4
- Infusion Partners of Melbourne, LLC Georgia4
- Infusion Partners, LLC Ohio4
- Infusion Solutions, Inc. New Hampshire4
- Intramed Plus Infusion & Medical Center, LLC South Carolina4
- Intramed Plus, Inc. South Carolina4
- Knoxville Home Therapies, LLC Tennessee4
- MedNow Infusion, LLC Delaware4
- Naven Health, Inc. Florida4
- New England Home Therapies, Inc. Massachusetts4
- OCH Infusion Centers (Colorado), LLC Delaware4
- OCH Infusion Centers (Texas), LLC Delaware4
- OCH Infusion Centers, LLC Delaware4
- OCH Infusion Clinic (Arizona), LLC Delaware4
- OCH Infusion Clinic (Illinois), LLC Delaware4
- OptioNet, Inc. Delaware4
- Option Care Enterprises, Inc. Delaware4
- Option Care Health, Inc. (f/k/a BioScrip, Inc.) Delaware4
- Option Care Home Care, Inc. Illinois4
- Option Care Infusion Services, Inc. Delaware4
- Option Care Infusion Services, LLC Tennessee4
- Option Care Infusion Suites, LLC Delaware4
- Option Care at Legacy Health, LLC Oregon4
- Option Care of New York, Inc. New York4
- Professional Home Care Services, Inc. Delaware4
- River City Pharmacy, Inc. California4
- Rochester Home Infusion, Inc. Minnesota4
- SPNN Holdings, LLC Delaware4
- Scott-Wilson, Inc. Kentucky4
- Specialty Pharma, Inc. Delaware4
- Springville Pharmacy Infusion Therapy, Inc. New York4
- Trinity HomeCare, LLC New Jersey4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Oct 6, 20268-K Entered a material agreement; Regulation FD disclosure95
- Jul 29, 20268-K Results of operations96
- May 22, 20268-K Shareholder vote97
- May 12, 20268-K Regulation FD disclosure98
- May 5, 20268-K Executive or director change99
- Apr 30, 20268-K Results of operations; Regulation FD disclosure100
- Apr 2, 20268-K Entered a material agreement; New debt or obligation101
- Feb 24, 20268-K Results of operations102
- Jan 12, 20268-K Results of operations; Regulation FD disclosure; Other events103
- Oct 30, 20258-K Results of operations104
- Sep 25, 20258-K Entered a material agreement; New debt or obligation105
- Aug 20, 20258-K Executive or director change; Regulation FD disclosure106
- Aug 7, 2019New chief executive John Charles Rademacher becomes CEO15
- Sep 23, 2016New chief executive Daniel E. Greenleaf becomes CEO16
- Nov 14, 2006New chief executive Richard H. Friedman becomes CEO17
- Mar 22, 1996Founded Option Care Health, Inc. is founded2
Calendar
Coming up
- Oct 29, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.40 a share, on Oct 30, 2025.107
When it reported results
- Jul 29, 2026Reported quarterly or annual results96
- Apr 30, 2026Reported quarterly or annual results100
- Feb 24, 2026Reported quarterly or annual results102
- Jan 12, 2026Reported quarterly or annual results103
- Oct 30, 2025Reported quarterly or annual results104
- Jul 30, 2025Reported quarterly or annual results108
- Apr 29, 2025Reported quarterly or annual results109
- Feb 26, 2025Reported quarterly or annual results110
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
365 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 50 major events, 215 insider forms, 29 large holders, 51 other. The latest 20:
- Oct 6, 2026DEFA14A EDGAR
- Oct 6, 2026DEFA14A EDGAR
- Oct 6, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Jul 29, 202610-Q EDGAR
- Jul 29, 20268-K EDGAR
- Jul 8, 20264 EDGAR
- Jul 8, 20263 EDGAR
- May 22, 20264 EDGAR
- May 22, 20264 EDGAR
- May 22, 20264 EDGAR
- May 22, 20264 EDGAR
- May 22, 20264 EDGAR
- May 22, 20264 EDGAR
- May 22, 20264 EDGAR
- May 22, 20264 EDGAR
- May 22, 20268-K EDGAR
- May 21, 20264 EDGAR
- May 12, 20268-K EDGAR
- May 7, 20264 EDGAR
The 365 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
42 open-market trades by officers, directors and large owners since October 2021: 16 buys and 26 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 7, 2026 | SULLIVAN TIMOTHY PDirector | Buy | 24,154 | $20.69 | $499.7K | Form 4 |
| May 4, 2026 | KRAEMER HARRY M JANSEN JRDirector | Buy | 36,610 | $21.41 | $783.8K | Form 4 |
| May 4, 2026 | Sethna MeenalChief Financial Officer | Buy | 16,225 | $20.16 | $327.1K | Form 4 |
| May 4, 2026 | RADEMACHER JOHN CHARLESChief Executive Officer | Buy | 12,500 | $21.18 | $264.8K | Form 4 |
| Feb 27, 2026 | Pate R CarterDirector | Sale | 30,287 | $32.05 | $970.7K | Form 4 |
| Feb 27, 2026 | Bavaro MichaelChief Human Resources Officer | Sale | 6,000 | $33.00 | $198.0K | Form 4 |
| Nov 3, 2025 | KRAEMER HARRY M JANSEN JRDirector | Buy | 38,000 | $25.98 | $987.2K | Form 4 |
| Sep 9, 2025 | Wright Norman L.Director | Buy | 3,411 | $29.31 | $100.0K | Form 4 |
| Aug 21, 2025 | SULLIVAN TIMOTHY PDirector | Buy | 20,000 | $27.51 | $550.2K | Form 4 |
| Aug 21, 2025 | GOLDING DAVID WDirector | Buy | 1,000 | $27.63 | $27.6K | Form 4 |
| Aug 20, 2025 | Pate R CarterDirector | Buy | 750 | $27.19 | $20.4K | Form 4 |
| Aug 20, 2025 | KRAEMER HARRY M JANSEN JRDirector | Buy | 36,000 | $27.15 | $977.4K | Form 4 |
| Feb 28, 2025 | Bavaro MichaelChief Human Resources Officer | Sale | 30,996 | $33.26 | $1.0M | Form 4 |
| Nov 8, 2024 | KRAEMER HARRY M JANSEN JRDirector | Buy | 43,000 | $22.54 | $969.2K | Form 4 |
| Sep 3, 2024 | Pate R CarterDirector | Sale | 1,465 | $32.37 | $47.4K | Form 4 |
| Aug 22, 2024 | SHAPIRO MICHAEL H.Chief Financial Officer | Sale | 23,217 | $30.95 | $718.6K | Form 4 |
| Aug 22, 2024 | SULLIVAN TIMOTHY PDirector | Sale | 47,249 | $30.91 | $1.5M | Form 4 |
| Aug 21, 2024 | BETTEN ELIZABETH QUADROSDirector | Sale | 47,531 | $31.09 | $1.5M | Form 4 |
| Aug 15, 2024 | Bavaro MichaelChief Human Resources Officer | Sale | 5,765 | $31.42 | $181.1K | Form 4 |
| Feb 28, 2024 | Bavaro MichaelChief Human Resources Officer | Sale | 1,984 | $31.73 | $63.0K | Form 4 |
All 42 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Durable Capital Partners LPSCHEDULE 13G/A, 2 filings Jun 13, 2025 to Aug 14, 2026111
- FMR LLCSCHEDULE 13G/A, 6 filings Feb 9, 2022 to May 6, 2026112
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 2026113
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 2026114
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 27, 2026115
- Wellington Management CompanySCHEDULE 13G/A, 3 filings Nov 8, 2024 to Aug 12, 2025116
- BlackRockSC 13G/A, 4 filings Feb 4, 2022 to Jan 23, 2024117
- Walgreens Boots AllianceSC 13D/A, 4 filings Dec 20, 2021 to Jun 12, 2023118
- PRICE T ROWE ASSOCIATES INC /MD/SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023119
- MADISON DEARBORN PARTNERS LLCSC 13D/A, 1 filing Dec 20, 2021120
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | John C. RademacherPresident and Chief Executive Officer | 59 | $1.0M | $9.3M121 |
| 2025 | Luke WhitworthChief Operating Officer | $625.0K | $3.8M121 | |
| 2025 | Michael ShapiroFormer Chief Financial Officer | $522.0K | $3.5M121 | |
| 2025 | Collin G. SmyserGeneral Counsel and Corporate Secretary | $500.0K | $2.2M121 | |
| 2025 | Christopher L. GrashoffChief Growth Officer | $1.1M | $1.9M121 | |
| 2025 | Meenal A. SethnaChief Financial Officer | $165.1K | $1.8M121 | |
| 2024 | John C. RademacherPresident and Chief Executive Officer | 59 | $1.0M | $8.2M121 |
| 2024 | Michael ShapiroFormer Chief Financial Officer | $611.6K | $4.1M121 | |
| 2024 | Luke WhitworthChief Operating Officer | $608.0K | $3.4M121 | |
| 2024 | Collin G. SmyserGeneral Counsel and Corporate Secretary | $488.7K | $1.9M121 | |
| 2024 | Christopher L. GrashoffChief Growth Officer | $400.0K | $1.7M121 | |
| 2023 | John C. RademacherPresident and Chief Executive Officer | 59 | $1.0M | $16.6M121 |
| 2023 | Michael ShapiroFormer Chief Financial Officer | $599.3K | $8.3M121 | |
| 2023 | Luke WhitworthChief Operating Officer | $542.4K | $3.5M121 | |
| 2023 | Collin G. SmyserGeneral Counsel and Corporate Secretary | $448.1K | $2.5M121 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 22,104,863 | $463.5M | 0.0% | +2,217,031 |
| Wellington Management Group Llp | 11,782,384 | $247.1M | 0.0% | −115,083 |
| Vanguard Portfolio Management LLC | 8,274,458 | $173.5M | 0.0% | +211,903 |
| Fuller & Thaler Asset Management, Inc. | 7,450,698 | $156.2M | 0.4% | +325,418 |
| Vanguard Capital Management LLC | 7,063,747 | $148.1M | 0.0% | +47,424 |
| Durable Capital Partners LP | 6,163,722 | $129.3M | 1.3% | −2,827,532 |
| State Street Corp | 6,139,898 | $128.8M | 0.0% | +265,018 |
| Arrowstreet Capital, Limited Partnership | 5,980,270 | $125.4M | 0.1% | +1,744,033 |
| Dimensional Fund Advisors LP | 5,449,294 | $114.3M | 0.0% | +1,572,438 |
| Geode Capital Management, LLC | 4,467,797 | $93.7M | 0.0% | +219,576 |
| Millennium Management LLC | 2,618,869 | $54.9M | 0.0% | +977,878 |
| Charles Schwab Investment Management Inc | 2,464,334 | $51.7M | 0.0% | −24,199 |
| Bank Of America Corp /de/ | 2,266,839 | $47.5M | 0.0% | +321,824 |
| Morgan Stanley | 2,240,837 | $47.0M | 0.0% | −573,415 |
| Goldman Sachs Group Inc | 2,165,092 | $45.4M | 0.0% | +791,302 |
| Sumitomo Mitsui Trust Group, Inc. | 2,132,614 | $44.7M | 0.0% | −478,333 |
| Northern Trust Corp | 1,961,486 | $41.1M | 0.0% | +16,486 |
| Boston Partners | 1,952,275 | $41.0M | 0.0% | −479,192 |
| Nuveen, LLC | 1,938,948 | $40.7M | 0.0% | +318,076 |
| Swedbank AB | 1,891,500 | $39.7M | 0.0% | +165,500 |
| Fmr LLC | 1,819,131 | $38.1M | 0.0% | −4,606,988 |
| Point72 Asset Management, L.P. | 1,800,244 | $37.8M | 0.1% | +1,237,540 |
| Norges Bank | 1,673,104 | $35.1M | 0.0% | New |
| Manufacturers Life Insurance Company, The | 1,633,818 | $34.3M | 0.0% | −171,053 |
| Citadel Advisors LLC | 1,633,556 | $34.3M | 0.0% | −1,903,902 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
4 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Oct 31, 2025 | Lisa C. McClainRepublican, House | Sale | $1,001 - $15,000 | −6.8% | Report |
| Oct 30, 2025 | Lisa C. McClainRepublican, House | Buy | $1,001 - $15,000 | +5.6% | Report |
| Oct 30, 2025 | Lisa C. McClainRepublican, House | Sale | $1,001 - $15,000 | −5.6% | Report |
| Sep 25, 2025 | Lisa C. McClainRepublican, House | Buy | $1,001 - $15,000 | −0.9% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Option Care Health, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGAROption Care Health, Inc.1
- CIK0001014739
- Employer ID (EIN)05-04896645
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)8082 Services-Home Health Care Services1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address3000 Lakeside Dr, Suite 300N, Bannockburn, IL 600151
- Phone312 940 24431
- Shares outstanding157,027,504 as of Apr 28, 202613
- Public float$5.3B as of Jun 30, 20255
- AuditorKPMG LLP, Chicago, Illinois PCAOB ID 185; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceJun 6, 19961
- Filings1,811 in all: 4 (683), 8-K (320), 3 (92), 10-Q (90), SC 13G/A (83), SC 13D/A (67), SC 13G (63), DEFA14A (53)1
All 57 form types
425 (31), DEF 14A (30), 10-K (28), 4/A (26), UPLOAD (25), CORRESP (20), S-8 (16), SC 13D (16), 8-K/A (11), 5 (10), 144 (9), 424B5 (9), EFFECT (9), S-3 (9), 10-Q/A (8), 424B4 (8), PRE 14A (7), S-4/A (7), 10-K/A (6), 8-A12G/A (5), CT ORDER (5), S-3/A (5), S-4 (5), SCHEDULE 13G/A (5), 3/A (4), S-1/A (4), SCHEDULE 13G (4), 424B3 (3), ARS (3), DEFM14A (3), S-8 POS (3), 10-K405 (2), 8-A12G (2), D (2), FWP (2), NT 10-K (2), PREM14A (2), PRER14A (2), RW (2), 10-K405/A (1), 424B1 (1), 424B7 (1), 8-A12B (1), 8-A12B/A (1), DEF 14C (1), DEFR14A (1), NT 10-Q (1), PRE 14C (1), S-1 (1)
- Latest filingsAnnual report (10-K) Feb 24, 2026
Quarterly report (10-Q) Jul 29, 2026
Proxy statement (DEF 14A) Apr 8, 2026
Latest 8-K (8-K) Oct 6, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.0001 par value per share | OPCH | Nasdaq Global Select Market |
From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Option Care Health, Inc. names in Item 1A of its 10-K filed Feb 24, 2026: 33 risks under these headings, as written.5
- Company-Specific Risk Factors
- Our revenue and profitability could decline if the pharmaceutical industry undergoes certain changes, including limiting or discontinuing research, development, production and marketing of the pharmaceuticals that are compatible with the services we provide.
- If we lose relationships with managed care organizations (“MCOs”) and other non-governmental third-party payers, we could lose access to a significant number of patients and our revenue and profitability could decline.
- Increasing competition from established and vertically integrated healthcare providers, coupled with industry consolidation and cost pressures, may limit our ability to grow revenue, maintain pricing, secure favorable contracts, and access critical pharmaceutical products.
- If we are unable to maintain relationships with existing patient referral sources, our business and consolidated financial condition, results of operations, and cash flows could be materially adversely affected.
- Changes in industry pricing benchmarks could adversely affect our financial performance.
- Changes in our relationships with pharmaceutical manufacturers, including changes in drug availability or pricing, could adversely affect our business and financial results.
- A disruption in pharmaceutical and medical supply could adversely impact our business.
- A shortage of qualified registered nursing staff, pharmacists and other professionals could adversely affect our ability to attract, train and retain qualified personnel and could increase operating costs.
- Introduction of new drugs, accelerated adoption of existing lower margin drugs or withdrawal of existing drugs could adversely affect our revenues and profitability when prescribers prescribe these drugs for their patients or they are mandated by Third-Party Payers.
- Our business could be adversely affected if we fail to effectively adopt and integrate evolving technologies such as artificial intelligence (“AI”), attract and retain necessary technical talent, or adapt to competitive, technological, or structural changes in the healthcare products and services industry, any of which could impair our ability to attract and retain clients and maintain our competitive position.
- Changes in future business conditions could cause business investments and/or recorded goodwill to become impaired, and our results of operations could suffer if there is an impairment of goodwill.
The other 22 risks
- A significant change in, or noncompliance with, governmental regulations and other legal requirements could have a material adverse effect on our reputation and profitability.
- Federal actions and legislation could reduce reimbursement rates from governmental payers and adversely affect our results of operations.
- Delays in reimbursement may adversely affect our liquidity, cash flows and results of operations.
- Ongoing reimbursement rate reductions, pricing pressures from Third-Party Payers and managed care payers, and increasing payer consolidation could significantly impact revenue, reduce profitability, and concentrate financial dependence on a few large payers.
- We face periodic reviews and billing audits by governmental and private payers, which could result in adverse findings that may negatively impact our business.
- If any of our pharmacies fail to comply with the conditions of participation in the Medicare program, that pharmacy could be terminated from Medicare, which could adversely affect our consolidated financial statements.
- Regulatory changes, increased scrutiny, or reclassification of our compounding practices as an FDA-regulated outsourcing facility could lead to costly compliance requirements, operational disruptions, and reputational harm.
- Our existing indebtedness could adversely affect our business and growth prospects.
- We may incur additional debt, which could increase the risks associated with our leverage.
- We may not be able to generate sufficient cash flow to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under such indebtedness, which may not be successful.
- Risks Relating to Our Common Stock
- Provisions of our corporate governance documents could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management, even if it is beneficial to our stockholders.
- Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.
- We cannot guarantee that our stock repurchase program will enhance long-term stockholder value.
- General Risk Factors
- Pending and future litigation could subject us to significant monetary damages and/or require us to change our business practices.
- We may be subject to liability claims for damages and other expenses that are not covered by insurance.
- Pressures relating to downturns in the economy could adversely affect our business and consolidated financial statements.
- Pursuing acquisitions or strategic investments and alliances may expose us to integration challenges, valuation uncertainties, operational disruptions, and potential financial losses if these investments fail to deliver expected benefits.
- Our business depends upon our information systems. A cyber-attack, security breach or our inability to effectively integrate, manage and keep our information systems secure and operational could disrupt our operations.
- Reliance on third-party hosting services exposes us to potential security breaches, service disruptions, and pricing changes that could negatively impact operations and financial performance.
- The development and use of AI technologies could expose us to significant governance, compliance, and legal liabilities, including evolving regulatory requirements, heightened scrutiny, litigation risk, and substantial compliance costs, that may adversely affect our operations, financial condition, and ability to successfully adopt and deploy AI.
- Failure to maintain effective internal control over our financial reporting could have an adverse effect on our ability to report our financial results on a timely and accurate basis.
- Acts of God, such as major weather disturbances or other force majeure events, could disrupt our business.
Legal proceedings
For a summary of material legal proceedings, if any, refer to Note 14, Commitments and Contingencies, of the consolidated financial statements included in Item 8 of this Annual Report.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22SEC EDGARHai Tran, Chief financial officer
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31SEC EDGARFemi Adewunmi, Chief Medical Officer
- 32
- 33
- 34
- 35
- 36SEC EDGARSeema Kumbhat, Chief Medical Officer
- 37
- 38SEC EDGARClifford E. Berman, Officer
- 39
- 40
- 41
- 42
- 43SEC EDGARAlex Schott, Senior Vice President
- 44
- 45
- 46
- 47SEC EDGARDonna Trujillo, SVP Human Resources
- 48
- 49
- 50
- 51
- 52
- 53SEC EDGARBarbara Cormier, Compliance Officer
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61SEC EDGARBrian J. Reagan, EVP
- 62SEC EDGARBarbara W. Bodem, Board member
- 63SEC EDGARNorman L. Wright, Board member
- 64SEC EDGAREric Brandt, Board member
- 65SEC EDGARAaron Friedman, Board member
- 66SEC EDGARAnita M. Allemand, Board member
- 67SEC EDGARElizabeth D. Bierbower, Board member
- 68SEC EDGARNatasha Deckmann, Board member
- 69SEC EDGARPaul J. Finnegan, Board member
- 70SEC EDGARAlan Troy Nielsen, Board member
- 71
- 72
- 73SEC EDGARJohn Arlotta, Board member
- 74SEC EDGARMark Edmund Vainisi, Board member
- 75SEC EDGARNitin Sahney, Board member
- 76SEC EDGARTimothy P. Sullivan, Board member
- 77SEC EDGARSteven Neumann, Board member
- 78SEC EDGARMichael G. Bronfein, Board member
- 79SEC EDGARAdam Gray, Board member
- 80SEC EDGARDavid W. Golding, Board member
- 81SEC EDGARMichael Goldstein, Board member
- 82SEC EDGARR. Carter Pate, Board member
- 83SEC EDGARTricia Nguyen, Board member
- 84SEC EDGARYon Jorden, Board member
- 85SEC EDGARRichard H. Friedman, Board member
- 86
- 87SEC EDGARCharlotte W. Collns, Board member
- 88SEC EDGARStuart A. Samuels, Board member
- 89SEC EDGARDavid R. Hubers, Board member
- 90SEC EDGARLouis Difazio Dr., Board member
- 91SEC EDGARMichael Kooper, Board member
- 92SEC EDGARMyron Z. Holubiak, Board member
- 93SEC EDGARRichard L. Robbins, Board member
- 94SEC EDGARKathryn Stalmack, General counsel
- 95
- 96SEC EDGARResults of operations
- 97SEC EDGARShareholder vote
- 98SEC EDGARRegulation FD disclosure
- 99SEC EDGARExecutive or director change
- 100
- 101
- 102SEC EDGARResults of operations
- 103
- 104SEC EDGARResults of operations
- 105
- 106
- 107NasdaqNasdaq calendar
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121